Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada Title Grant Type Focus Area Country Application Due Date NSCLC Biomarker TestingRelease Date:Quality Improvement Oncology Andorra, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Liechtenstein, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Spain, Sweden, Switzerland, USA, United Kingdom Development of Talazoparib for Prostate CancerRelease Date:Partner: National Comprehensive Cancer NetworkResearch Oncology USA Approaches to Smoking Cessation CounselingRelease Date:Education Internal Medicine Australia, India, Japan, New Zealand, Singapore, Taiwan Burden of Community Acquired PneumoniaRelease Date:Research Vaccines USA Closing Knowledge Gaps in Moderate-to-Severe Alopecia AreataRelease Date:Education Inflammation & Immunology USA Progress in Androgen Deprivation Therapy (ADT) in Advanced Prostate CancerEducation Oncology USA Efforts to Promote Team-based Care and Regional Medical Collaboration for Cancer PatientsRelease Date:Partner: Japan Society of Clinical OncologyQuality Improvement Oncology Japan ISID-Pfizer 2021 Grant ChallengeRelease Date:Partner: The International Society for Infectious Diseases (ISID)Quality Improvement Hospital All Data generation on the treatment of Metastatic Breast Cancer with CDK 4/6 inhibitorsRelease Date:Research Oncology Portugal China Medical Education in Breast Cancer Diagnosis and TreatmentRelease Date:Education Oncology China Hemophilia: Improve Knowledge Level of Gene TherapyRelease Date:Education Rare Disease Japan Understanding Healthcare disparities in IBD Patients in Underserved CommunitiesRelease Date:Quality Improvement Inflammation & Immunology Canada, USA